Sucessful DRF toxicology Study

24 July 2024 💥We are delighted to announce that the O2L-001 technology developed by Op2Lysis to treat massive and deep cerebral haemorrhage 🩸🧠 has reached a new milestone. The first “Dose Range Finding” safety study has produced very positive results. This success means that highly effective doses can be used in clinical trials.

Retrospective – 2023 in a nutshell

There are still a few days left to wish a very Happy New Year 2024 to our community, our investors, our readers and all those who make the Op2Lysis program live, progress and bring new hope to hemorrhagic stroke patients every day 🧓🧠🩸. We are therefore delighted to share with you the progress made in […]

Nominated for the GALIEN USA 2023 award “Best Startup”

Op2Lysis has been nominated for the Prix GALIEN USA 2023, in the Best StartUp category. The Prix Galien recognises outstanding achievements in improving human health and well-being around the world through the development of drugs, medical devices and other innovative approaches to better manage disease. The press release is available below:

Op2Lysis is a silver sponsor of the WICH 2023 conference and will have the opportunity to give two oral presentations to an expert audience  in cerebral haemorrhage

The World Intracranial Hemorrhage Conference (WICH) meets every two years and brings together neurologists, neurosurgeons, researchers and clinicians from all fields, healthcare providers, students and community members from around the world to provide a unique opportunity to exchange ideas and share research and clinical innovations in the field of intracranial haemorrhage. The WICH 2023 conference […]

Retrospective – 2022 in a nutshell

In 2022, Op2Lysis has taken on a new dimension with the support of the EIC Accelerator in Europe, Bpifrance in France and Win4Company in Belgium. The following sections describe the company’s progress on corporate, technical and  regulatory fronts. We would also like to take this opportunity to wish a happy new year 2023 to all […]